Breast Cancer Diagnostics
Total Trials
1
As Lead Sponsor
0
As Collaborator
Total Enrollment
226
NCT04624256
Germline DNA-Based Radiosensitivity Biomarker Influence on Toxicity Following Prostate Radiotherapy, GARUDA Trial
Phase: N/A
Role: Collaborator
Start: Nov 10, 2020
Completion: Dec 31, 2028
Loading map...